Taking Risk Prediction to the Next Level. Advances in Biomarker Research for Atherosclerosis

Author(s): Marten Siemelink, Sander van der Laan, Leo Timmers, Imo Hoefer, Gerard Pasterkamp

Journal Name: Current Pharmaceutical Design

Volume 19 , Issue 33 , 2013

Become EABM
Become Reviewer
Call for Editor


Advances in risk prediction are necessary to stem the tide of the increasing incidence of global cardiovascular disease. Newly discovered biomarkers are needed for primary and secondary prevention and will undoubtedly play a major role in drug development programs and monitoring of treatment efficacy. The combination of improved -omics technologies and the investigation of relatively untapped sources of biomarkers will likely result in risk algorithms that will add value on top of the traditional risk factors. New sources of biomarkers are being explored with encouraging results. These include microvesicles, microRNAs, circulating cells and atherosclerotic plaques. We will review these sources for their potential for new biomarkers. Furthermore, the major impact of advances in genetics on risk prediction and biomarker development programs will be discussed.

Keywords: Atherosclerosis, cardiovascular, novel, biomarkers, discovery, drug

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 31 July, 2013
Page: [5929 - 5941]
Pages: 13
DOI: 10.2174/13816128113199990371
Price: $65

Article Metrics

PDF: 40